产品
编 号：F761466
分子式：C8H8Cl3N3NaO4S2
分子量：403.65
分子式：C8H8Cl3N3NaO4S2
分子量：403.65
产品类型
规格
价格
是否有货
结构图
CAS No: 91996-54-2
产品详情
生物活性：
Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model.
体内研究：
Trichlormethiazide (1 mg/kg; p.o.; once) sodium increases urinary volume, sodium and potassium excretion in rats.Trichlormethiazide (10 mg/kg, i.v.; daily for 5 days) sodium significantly reduces mean arterial pressure (MAP) within 24 h in high salt intake (HS) rats receiving angiotensin II, but does not affect MAP in any other group.Animal Model:Male Wistar rats, weighing 170-300 g
Dosage:1 mg/kg
Administration:Oral administration, once
Result:Significantly increased potassium excretion in normal rats. Significantly increased urinary volume, sodium and potassium excretion in cisplatin-induced ARF (acute renal failures) rats.
Animal Model:Male Sprague-Dawley rats (350-450 g)
Dosage:10 mg/kg
Administration:Intravenous injection, daily, for 15 days
Result:Produced a significant fall in MAP in rats on combined angiotensin II and high salt intake.
Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model.
体内研究：
Trichlormethiazide (1 mg/kg; p.o.; once) sodium increases urinary volume, sodium and potassium excretion in rats.Trichlormethiazide (10 mg/kg, i.v.; daily for 5 days) sodium significantly reduces mean arterial pressure (MAP) within 24 h in high salt intake (HS) rats receiving angiotensin II, but does not affect MAP in any other group.Animal Model:Male Wistar rats, weighing 170-300 g
Dosage:1 mg/kg
Administration:Oral administration, once
Result:Significantly increased potassium excretion in normal rats. Significantly increased urinary volume, sodium and potassium excretion in cisplatin-induced ARF (acute renal failures) rats.
Animal Model:Male Sprague-Dawley rats (350-450 g)
Dosage:10 mg/kg
Administration:Intravenous injection, daily, for 15 days
Result:Produced a significant fall in MAP in rats on combined angiotensin II and high salt intake.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备